InsiderTrades.com logo
We recommended Nvidia in 2016, now we’re recommending this…
From Porter & Company   |   Ad
The AI boom is just getting started. And the real wealth has still to be made…
You must read this new presentation from Porter Stansberry.

KYTX Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $9,900,000.00
Insider Selling (Last 12 Months): $0.00

Kyverna Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Kyverna Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Kyverna Therapeutics Share Price & Price History

Current Price: $5.53
Price Change: ▲ Price Increase of +0.18 (3.36%)
As of 10/30/2024 01:02 PM ET

This chart shows the closing price history over time for KYTX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Urgent: This election is rigged
From Porter & Company   |   Ad
If you missed it, my emergency election broadcast is now available - but will be removed soon
Click here to watch it now.

Kyverna Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/12/2024Northpond Ventures Iii Gp, LlcMajor ShareholderBuy450,000$22.00$9,900,000.00450,000View SEC Filing Icon  
See Full Table
625,000% Gain
From Crypto Swap Profits   |   Ad
The recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull run is over. But if history has taught us anything, it’s that this is only the beginning.
>> Dive into the Workshop Here

SEC Filings (Institutional Ownership Changes) for Kyverna Therapeutics (NASDAQ:KYTX)

18.08% of Kyverna Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at KYTX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Kyverna Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
10/24/2024Novo Holdings A S1,850,000$9.05M0.4%+5.7%4.291%Search for SEC Filing on Google Icon
10/11/2024Creative Planning11,028$54K0.0%N/A0.026%Search for SEC Filing on Google Icon
8/26/2024Teachers Retirement System of The State of Kentucky21,410$0.16M0.0%+69.7%0.050%Search for SEC Filing on Google Icon
8/20/2024Novo Holdings A S1,750,000$13.13M0.7%+150.0%4.059%Search for SEC Filing on Google Icon
8/15/2024The Manufacturers Life Insurance Company37,794$0.28M0.0%+32.6%0.088%Search for SEC Filing on Google Icon
8/15/2024Millennium Management LLC923,082$6.92M0.0%+32.8%2.141%Search for SEC Filing on Google Icon
8/15/2024MBB Public Markets I LLC410,191$3.08M0.1%N/A0.951%Search for SEC Filing on Google Icon
8/15/2024Deerfield Management Company L.P. Series C1,983,000$14.87M0.2%+35.6%4.599%Search for SEC Filing on Google Icon
8/15/2024Affinity Asset Advisors LLC200,000$1.50M0.2%N/A0.464%Search for SEC Filing on Google Icon
8/14/2024Great Point Partners LLC499,152$3.74M0.7%+232.8%1.158%Search for SEC Filing on Google Icon
8/14/2024Marshall Wace LLP10,400$78K0.0%-93.3%0.024%Search for SEC Filing on Google Icon
8/13/2024Skandinaviska Enskilda Banken AB publ26,195$0.20M0.0%+55.8%0.061%Search for SEC Filing on Google Icon
8/12/2024XTX Topco Ltd83,286$0.63M0.1%N/A0.193%Search for SEC Filing on Google Icon
8/12/2024E Fund Management Co. Ltd.189,432$1.42M0.1%N/A0.439%Search for SEC Filing on Google Icon
8/10/2024Sofinnova Investments Inc.47,850$0.36M0.0%+378.5%0.111%Search for SEC Filing on Google Icon
8/8/2024Federated Hermes Inc.16,000$0.12M0.0%N/A0.037%Search for SEC Filing on Google Icon
8/3/2024TD Asset Management Inc90,242$0.68M0.0%N/A0.209%Search for SEC Filing on Google Icon
8/1/2024Rhumbline Advisers20,007$0.15M0.0%N/A0.046%Search for SEC Filing on Google Icon
7/26/2024Bank of New York Mellon Corp55,790$0.42M0.0%N/A0.129%Search for SEC Filing on Google Icon
6/4/2024DekaBank Deutsche Girozentrale7,500$0.18M0.0%N/A0.017%Search for SEC Filing on Google Icon
5/28/2024Teachers Retirement System of The State of Kentucky12,614$0.31M0.0%N/A0.029%Search for SEC Filing on Google Icon
5/17/2024Artal Group S.A.200,000$4.97M0.1%N/A0.464%Search for SEC Filing on Google Icon
5/16/2024Janus Henderson Group PLC606,500$15.04M0.0%N/A1.407%Search for SEC Filing on Google Icon
5/16/2024Bain Capital Life Sciences Investors LLC3,163,868$78.59M6.3%N/A7.338%Search for SEC Filing on Google Icon
5/16/2024Blackstone Inc.100,000$2.48M0.0%N/A0.232%Search for SEC Filing on Google Icon
5/15/2024Price T Rowe Associates Inc. MD929,634$23.09M0.0%N/A2.156%Search for SEC Filing on Google Icon
5/15/2024Avoro Capital Advisors LLC475,000$11.80M0.1%N/A1.102%Search for SEC Filing on Google Icon
5/14/2024StemPoint Capital LP41,000$1.02M0.3%N/A0.095%Search for SEC Filing on Google Icon
5/10/2024Vanguard Group Inc.264,215$6.56M0.0%N/A0.613%Search for SEC Filing on Google Icon
5/2/2024Jennison Associates LLC1,398,659$34.74M0.0%N/A3.244%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Kyverna Therapeutics logo
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Read More on Kyverna Therapeutics

Today's Range

Now: $5.53
Low: $5.34
High: $5.69

50 Day Range

MA: $6.19
Low: $4.45
High: $8.40

52 Week Range

Now: $5.53
Low: $4.40
High: $35.06

Volume

99,619 shs

Average Volume

471,065 shs

Market Capitalization

$238.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Kyverna Therapeutics?

Kyverna Therapeutics' top insider investors include:
  1. Northpond Ventures Iii Gp, Llc (Major Shareholder)
Learn More about top insider investors at Kyverna Therapeutics.

Who are the major institutional investors of Kyverna Therapeutics?

Kyverna Therapeutics' top institutional investors include:
  1. Novo Holdings A S — 4.29%
  2. Creative Planning — 0.03%
Learn More about top institutional investors of Kyverna Therapeutics stock.

Which institutional investors are buying Kyverna Therapeutics stock?

Within the previous quarter, KYTX stock was purchased by institutional investors including:
  1. Novo Holdings A S
  2. Creative Planning
We recommended Nvidia in 2016, now we’re recommending this…
From Porter & Company   |   Ad
The AI boom is just getting started. And the real wealth has still to be made…
You must read this new presentation from Porter Stansberry.